TrialDiabetes, obesity & metabolism2020

Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase-4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials.

Andrej Janez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.